At RYVU we

Develope therapeutics at the forefront of oncology

Multi-target research collaboration

Biontech x RYVU several small molecule immunotherapy programs

Develope therapeutics at the forefront of oncology

Who We Are

Our mission is to transform the landscape of oncology
by targeting emerging biological pathways and delivering
novel solutions for patients in need.

Well-being of patients

At RYVU Therapeutics, our foremost priority is the well-being
of patients. We are committed to developing modern,
groundbreaking treatments for those suffering from various conditions,
particularly in the realm of oncology.

We innovate treatment approaches

We are developing a varied portfolio of targeted therapies
to treat cancers and solid tumors.

Our pipeline

STING STANDALONE

Solid tumors

PRMT5

Solid tumors

SEL24 (MEN1703) PIM/FLT3

DLBCL

RVU120 CDK8/19

R/R AML (RIVER-81, COMBINATION THERAPHY)

Discovery

Preclinical

Phase I

Phase II

Contact

FOR MEDICAL PROFFESIONALS & INVESTIGATORS

If you are a medical professional, an investigator
for a RYVU trial, or would like information about becoming an investigator, please contact us
investigators@ryvu.com or use contact form.